Xcout Intel
ABSCINT competitors & alternatives
The 12 closest competitors and alternatives to ABSCINT among diagnostics companies — ranked by similarity to what ABSCINT actually does, not by market-cap band.
Subscribe to see ABSCINT’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ABSCINT
ABSCINT is a clinical-stage biotechnology company that develops platform production processes for rapid creation of cold kits for molecular imaging in oncology and immunology. Headquartered in Belgium, the privately held firm focuses on innovative diagnostic and therapeutic applications using single-domain antibodies.
ABSCINT at a glance
ABSCINT is a diagnostics company headquartered in Belgium. Its most recent funding round raised $3M in September 2023. Xcout tracks 17 named people at ABSCINT, including Karine Clauwaert (Chief Executive Officer).
ABSCINT leadership
- Karine ClauwaertChief Executive Officer
- Koen DewaelePresident of the Board
- Martine VandermarliereChief Technical Officer
- Philippe VanwolleghemChief Quality and Regulatory Officer
- Catherine SkaClinical Operations and QA Manager
- Dieter FrijnsClinical Operations and Medical Affairs Lead
11 more named people on record for ABSCINT, with roles, board committees and tenure — see the full roster →
ABSCINT funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $3M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 ABSCINT competitors
Ranked by semantic similarity — how close each company is to ABSCINT by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
ImaginAb, Inc. is a global biotechnology company headquartered in California, with operations in Los Angeles and San Diego. It focuses on developing next-generation imaging and radiopharmaceutical products for cancer immunology.
Biotechnology
On Target Laboratories, Inc. is a biotechnology company founded in 2010 and headquartered in West Lafayette, Indiana. It discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery.
Health Care
Spago Nanomedical is a clinical-stage pharmaceutical company that develops precision nanomedicine products for the diagnosis and treatment of cancer and other severe diseases. Its pipeline includes Tumorad, a targeted radionuclide therapy for various cancers, and SpagoPix, a polymeric contrast agent designed to improve the precision of MRI diagnostics.
Biotechnology
Merus N.V. is a clinical-stage oncology company that discovers and develops antibody treatments for cancer using its proprietary Multiclonics platform. The company serves patients with cancer by advancing innovative therapeutic pipelines. Merus operates as part of Genmab.
Biotechnology
Anaveon is a late-stage preclinical biotechnology company based in Basel, Switzerland, focused on developing engineered antibodies for immunotherapy.
Biotechnology
Precirix is a clinical-stage biotechnology company dedicated to improving outcomes by developing precision radiopharmaceuticals for cancer therapy. Operating within the biotechnology research sector, the Brussels-based firm launched products such as CAM-FAP-Ga.
Biotechnology
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Biotech
AbCellera is a biotechnology company that integrates biology, computation, and engineering to discover and develop antibody-based medicines. The company operates a proprietary technology platform to advance internal and partnered drug programs across therapeutic areas such as endocrinology, immunology, autoimmunity, and oncology.
Biotechnology
Headquartered in Hanover, Germany, Phaeosynt is a biotechnology company founded to produce animal-free antibodies using diatoms instead of traditional methods.
Biotech
Philogen is a Swiss-Italian biotechnology company that focuses on the research, development, and commercialization of targeted therapeutics for the treatment of cancer and other serious conditions. The company utilizes proprietary antibody-based technologies to develop biopharmaceuticals, immunotherapies, and radio-conjugates for oncology and imaging applications.
Biotechnology
Merus N.V. is a Netherlands-based clinical-stage biotechnology company headquartered in Utrecht. It develops innovative antibody therapeutics, including Biclonics bispecific antibodies, primarily for the treatment of cancer and other serious diseases, serving patients through partnerships and clinical development programs.
Biotech
Affimed N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of cancer immunotherapies, with operations spanning the United States, Germany, and the rest of Europe. The company's primary investigational therapy, AFM13, has successfully completed a Phase II clinical study for peripheral T-cell lymphoma. This same candidate is also currently undergoing Phase IIa clinical trials for CD30-positive lymphoma and is in Phase I trials for Hodgkin lymphoma. Beyond its lead product, Affimed is advancing several other promising pipeline compounds. AFM24, a tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptors and CD16A, is presently in Phase IIa clinical trials for the treatment of various advanced cancers. Additionally, two other innate cell engagers (ICEs) are in preclinical development: AFM28, which is being investigated for acute myeloid leukemia, and AFM32, a candidate focused on the treatment of solid tumors. Affimed N.V. has formed strategic partnerships with esteemed institutions and companies, including The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. The company also receives research funding through an agreement with The Leukemia & Lymphoma Society. Founded in 2000, Affimed N.V. was initially known as Affimed Therapeutics B.V. before officially changing its name in October 2014. Its corporate headquarters are located in Heidelberg, Germany.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ABSCINT and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ABSCINTand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →